Medy-Tox, Inc.
Industry Group: Pharmaceuticals
Country/Region: South Korea
Identifier: KRX:086900
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 820 out of 853
Universe
Global Universe 13924 out of 15120
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
AnaptysBio, Inc. |
25.4
Medium
|
201 out of 853 |
Oxford Biomedica Plc |
32.5
High
|
539 out of 853 |
Basilea Pharmaceutica AG |
38.1
High
|
777 out of 853 |
Humacyte, Inc. |
38.6
High
|
786 out of 853 |
Medy-Tox, Inc. |
40
High
|
820 out of 853 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Medy-Tox, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Medy-Tox, Inc.'s Management of ESG Material Risk is Weak
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Medy-Tox, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level